The ACURATE neo transcatheter aortic valve system

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Medical Device Technology

Background:

• Severe symptomatic aortic stenosis requires intervention, with transcatheter aortic valve implantation (TAVI) emerging as a key treatment modality.
• The ACURATE neo is a second-generation, self-expanding TAVI system featuring a supra-annular design and unique 'top-down' deployment.
• This device aims to minimize left ventricular outflow-tract protrusion, potentially reducing conduction abnormalities.

Purpose of the Study:

• To review the characteristics and clinical outcomes of the ACURATE neo TAVI system.
• To assess the safety and efficacy of the ACURATE neo valve based on available observational data.
• To identify areas for future research and device development in TAVI.

Main Methods:

• Information was compiled from published manuscripts retrieved via MEDLINE searches.
• Conference presentations and trial data were also incorporated into the review.
• Expert commentary was provided based on the synthesized evidence.

Main Results:

• Observational data indicate low rates of all-cause mortality with the ACURATE neo TAVI.
• The device is associated with low rates of paravalvular leak and permanent pacemaker requirement.
• The transfemoral and transapical delivery systems facilitate a 'top-down' deployment.

Conclusions:

• TAVI with the ACURATE neo demonstrates favorable short-term outcomes in observational studies.
• Randomized comparative data and long-term durability studies are pending.
• Ongoing device modifications are expected to further enhance TAVI performance and reduce paravalvular leak.